Where is Humacyte located?

Humacyte is headquartered in Durham, United States. It is registered at Durham, North Carolina.

How many employees does Humacyte have?

As of Sep 30, 2026, the latest employee count at Humacyte is 159.

Is Humacyte a funded company?

Humacyte is a funded company, having raised a total of $425M across 14 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round.

When was the latest funding round of Humacyte?

Humacyte's latest funding was a $***** Venture Debt round on Apr 14, 2021, with participation from 1 investor. Its primary sector is Regenerative Medicine. In United States, the Regenerative Medicine sector has seen $58.5M in funding in 2026 to date.

What is the annual revenue of Humacyte?

Annual revenue of Humacyte is between $1M and $10M as on Dec 31, 2025

Where does Humacyte rank among its competitors?

Humacyte ranks 2nd amongst 41 active competitors, of which 7 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was TYBR Health, which secured $30M in Jul, 2026.

Who are the top competitors of Humacyte?

Humacyte's top competitors include AxoGen, Acera Surgical and TYBR Health. Among them, TYBR Health secured the most recent funding round in July, 2026.

Humacyte - 2026 Company Profile, Team, Funding, Competitors & Financials

Humacyte is a public company based in Durham (United States), founded in 2004 by Shannon Dahl. It operates as a Provider of human tissue-based products for vascular disease. Humacyte has raised $425M in funding from Access Industries and Fresenius Medical Care. The company has 41 active competitors, including 7 funded and 14 that have exited. Its top competitors include companies like AxoGen, Acera Surgical and TYBR Health.

Company Details

Humacyte is developing human tissue-based products for applications in vascular surgery. The company uses its proprietary platform technology to bioengineer human, extracellular matrix-based tissues into acellular tubes, etc., with properties similar to native tissues, suitable for any patient. The company is primarily focused on developing products for the replacement of arterial, venous tissues damaged by vascular diseases. Humacyte received a Fast Track designation from the US FDA in 2014.

Website: humacyte.com
Social
Email ID: *****@humacyte.com
Phone Number: +1 **********
Registered Address: Durham, North Carolina

Key Metrics

Founded Year

2004

Location

Durham, United States

Stage

Public

Total Funding

$425M in 14 rounds

Latest Funding Round

Venture Debt, Apr 14, 2021, $*****

Investors

Access Industries & 16 more

Ranked

2^nd among 41 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2025

Employee Count

159 as on Sep 30, 2026

Similar Companies

AxoGen & 44 more

Exit Details

Public

View Humacyte's full profile

Humacyte is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Humacyte, Inc. CIN: 1818382 , United States, Active		-	-	-
Humacyte Global, Inc. CIN: 32082588446 , United States, Active	Jan 04, 2022	-	-	-
Humacyte, Inc. CIN: 1818382 , United States, Active		$1M - $10M (As on Dec 31, 2025)	-	-
HUMACYTE GLOBAL, INC. CIN: 841661297 , United States, Active	Dec 31, 1999	-	221 (As on Dec 31, 2024)	-

Humacyte got listed on Aug 27, 2021.

Click here to take a look at Humacyte's IPO in detail

Humacyte has raised a total funding of $425M over 14 rounds. Its latest funding round was a Venture Debt round on Apr 14, 2021 for $*****. 1 investor participated in its latest round. Humacyte has 15 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Humacyte:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 14, 2021	2846083	Venture Debt	6811293	4822389	8414543	9964041
Jun 11, 2018	4987979	Series D	6860813	4712735	1400317	2003014
Feb 23, 2018	9648218	Series C	6513217	1434955	8474095	5613440

Access funding benchmarks and valuations. Sign up today!

View details of Humacyte's funding rounds and investors

The founders of Humacyte is Shannon Dahl.

Here are the details of Humacyte's key team members:

Shannon Dahl: Co-Founder & VP of Humacyte.

View details of Humacyte's Founder profiles and Board Members

Humacyte's employee count trend

Humacyte has 159 employees as of Sep 26. Here is Humacyte's employee count trend over the years:

Uncover Humacyte's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Humacyte include AxoGen, Acera Surgical and TYBR Health. Here is the list of Top 10 competitors of Humacyte, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AxoGen 2002, Alachua (United States), Public	Developer of therapies for the repair of peripheral nerve injuries	$62.4M	Oberland Capital, Cardinal Partners & 10 others	67/100
2nd	Humacyte 2004, Durham (United States), Public	Provider of human tissue-based products for vascular disease	$425M	Access Industries, Oberland Capital & 15 others	63/100
3rd	Acera Surgical 2013, St. Louis (United States), Acquired	Provider of synthetic electrospun scaffolds for regenerative medical applications	$6.32M	St. Louis Arch Angels, Missouri Technology ... & 1 others	59/100
4th	TYBR Health 2020, Houston (United States), Series A	Provider of regenrative medicine for post surgical scarring	$38.4M	Vensana Capital, Y Combinator & 4 others	58/100
5th	Tissue Regenix 2006, Swillington (United Kingdom), Public	Developer of regenerative medical devices by using cell technology	-	Harwood Capital, IP Group & 2 others	53/100
6th	CUTISS 2017, Zurich (Switzerland), Series C	Company developing personalized skin tissue therapeutics for skin defect treatments	$157M	Cherry Bay Capital Group, Rode Kruis Ziekenhuis ... & 15 others	53/100
7th	Aroa Biosurgery 2008, Mangere (New Zealand), Public	Developer of medical and surgical products for soft tissue reconstruction	-	Alium Capital, Cure Kids Ventures & 2 others	51/100
8th	Heartseed 2015, Minato (Japan), Public	Developer of myocardial regenerative medicine for treating heart diseases	$76.7M	Sumitomo Mitsui Trust Holdings, SBI Group ... & 18 others	48/100
9th	Epibone 2013, Brooklyn (United States), Series B	Developer of patient‑specific bone and cartilage grafts	$48.6M	Kendall Capital Partners, MBX Capital & 25 others	48/100
10th	CorMatrix 2001, Roswell (United States), Series C	Cardiovascular regeneration leader, healing hearts with innovative solutions	$55.2M	JAM Capital Partners, Purdue	43/100